InMed Pharmaceuticals Inc. (INM)
NASDAQ: INM · IEX Real-Time Price · USD
0.350
+0.018 (5.36%)
Mar 28, 2024, 10:39 AM EDT - Market open

InMed Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jul - Jun.
Year Current2023202220212020
Market Capitalization
23726-
Market Cap Growth
--55.23%-73.10%--
Enterprise Value
-7-5118-6
PE Ratio
-0.34-0.39-0.37-2.51-
PS Ratio
0.380.756.32--
PB Ratio
0.160.260.763.47-
P/FCF Ratio
-0.34-0.41-0.44-2.61-
P/OCF Ratio
-0.34-0.42-0.44-2.61-
EV/Sales Ratio
-1.28-1.330.98--
EV/EBITDA Ratio
1.220.75-0.06-1.920.63
EV/EBIT Ratio
1.110.69-0.06-1.880.62
EV/FCF Ratio
1.080.74-0.07-1.890.75
Debt / Equity Ratio
0.030.030.040.040.05
Debt / EBITDA Ratio
-0.06-0.05-0.02-0.03-0.04
Debt / FCF Ratio
-0.06-0.05-0.03-0.03-0.04
Quick Ratio
5.924.611.903.353.52
Current Ratio
7.035.662.893.783.77
Asset Turnover
0.400.270.0700
Interest Coverage
----27.31-
Return on Equity (ROE)
-54.30%-63.80%-150.70%-136.60%-88.90%
Return on Assets (ROA)
-46.20%-52.70%-114.50%-100.80%-76.90%
Return on Capital (ROIC)
-53.25%-67.22%-182.06%-129.97%-147.71%
Earnings Yield
-305.44%-257.74%-270.06%-39.85%-
FCF Yield
-312.97%-241.44%-226.83%-38.25%-
Buyback Yield / Dilution
-246.59%-336.58%-108.65%-28.72%-0.55%
Total Shareholder Return
-246.59%-336.58%-108.65%-28.72%-0.55%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).